Not yet recruitingInterventionalPhase 2Last updated Aug 12, 2026

CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension

A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study, to Compare the Efficacy and Safety/Tolerability of CS1 Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

Overview

ClinicalTrials.gov ID: NCT07761572
Lead Sponsor: Cereno Scientific ABINDUSTRY
Brief Summary: This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension.

Participants completing Treatment Period 1 (Week 36) will be re-randomized to continue or switch study treatment for Treatment Period 2 through Week 52.
Study Type

Status

Overall Status: Not yet recruiting
Start Date: Sep 15, 2026Estimated
Primary Completion Date: Feb 2, 2029Estimated
Completion Date: Apr 30, 2029Estimated

Study Record Dates

First Submitted: Aug 6, 2026
First Submitted that Met QC Criteria: Aug 6, 2026
First Posted: Aug 12, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 6, 2026
Last Update Posted: Aug 12, 2026Actual
Last Verified: Aug 2026

NCT05224531Completed

Effect of CS1 in Subjects With Pulmonary Arterial Hypertension

NCT07143448Not yet recruiting

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

NCT06321705Available

Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension

NCT06493461Terminated

A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults

NCT03496207Completed

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT06137742Active, not recruiting

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension